BACILLUS CALMETTE-GUERIN CAN SUBVERT PATIENTS ANTITUMOR IMMUNE RESPONSE BY DOWNREGULATING HLA-I EXPRESSION ON CANCER CELLS

¹Mathieu Rouanne*, ²Julien Adam, ¹Camelia Radulescu, ¹Diane Letourneur, ¹Severine Mouraud, ¹Delphine Bredel, ¹Anne-Gaelle Goubet, ³Tuan Zea Tan, ¹Amelie Bigorgne, ⁴Michael Dussiot, ¹Lambros Tselikas, ¹Sandrine Susini, ¹François-Xavier Danlos, ¹Roman Chabanon, ¹Nicolas Signolle, ¹Anna Schneider, ⁵Sophie Vacher, ⁵Ivan Bieche, ¹Thierry Lebreton, ¹Yves Allory, ¹Jean-Charles Soria, ⁶Jean Paul Thiery, ¹Laurence Zitvogel, ¹Aurelien Marabelle. ¹Gustave Roussy, New York, NY, France; ²Hopital Paris Saint Joseph, Paris, France; ³Cancer Institute Singapore, Singapore, Singapore; ⁴Institut Imagine, Paris, France; ⁵Curie Institute, Paris, France; ⁶Singapore Cancer Institute, Singapore, Singapore

Background Patients with high-risk non muscle-invasive bladder cancer (NMIBC) frequently relapse after standard BCG immunotherapy and have a dismal outcome after progression to muscle-invasive bladder cancer (MIBC).^{1 2} The mechanisms of tumor resistance to such immunotherapy remain elusive.

Methods We performed functional assays of fresh human bladder tumors mixed with BCG, reinforced with in vitro experiments and in situ transcriptomics analyses together with immune profiling by immunohistochemistry (IHC) in a cohort of T1 NMIBC pre- and post BCG therapy.

Results We found two distinct patterns of BCG-induced immune subversion. In the first pattern, intracellular infection by live BCG was associated with HLA-I loss and epithelial-to-mesenchymal transition characteristics. Mechanistically, LC3-GFP reporter cell line showed a significant induction of autophagy upon BCG exposure. HLA-I deficient tumors displayed a myeloid immunosuppressive microenvironment together with an upregulation of autophagy-related genes, and dismal outcome. Conversely, HLA-I+ BCG-treated tumors generated a Th1 type of immune response associated with an upregulation of exhaustion markers. Such patients had a very favorable outcome upon radical surgery.

Conclusions We surmise that HLA-I expression in bladder cancers does not result from immunoediting but rather from HLA-I molecules endocytosis related to autophagy induction in infected cancer cells. Cancer cells HLA-I scoring by immunohistochemistry staining can be easily implemented by pathologists in routine practice to stratify future bladder cancer patient treatment strategies.

REFERENCES

1. Pietzak EJ, Zabor EC, Bagrodia A, *et al.* Genomic differences between "primary" and "secondary" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. *Eur Urol* 2019;**75**(2):231–239.
2. Patrick J Hensley, Kelly K Bree, Matthew T Campbell, *et al.* Progression of disease after BCG therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy. *J Urol* 2021 June 29;101097JU000000000000001943.

Ethics Approval Our study obtained ethics approval from the Foch Hospital Ethics Committee (IRB00012437). All the participants gave informed consent before taking part.

Consent We surmise that HLA-I expression in bladder cancers does not result from immunoediting but rather from HLA-I molecules endocytosis related to autophagy induction in infected cancer cells. Cancer cells HLA-I scoring by immunohistochemistry staining can be easily implemented by pathologists in routine practice to stratify future bladder cancer patient treatment strategies.

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.901>